CytomX Therapeutics, Inc.
US ˙ NasdaqGS ˙ US23284F1057

SecurityCTMX / CytomX Therapeutics, Inc.
InstitutionDimensional Fund Advisors Lp
Latest Disclosed Ownership1,930,920 shares
Latest Disclosed Value $ 9,071,290
Dimensional Fund Advisors Lp reports 49.72% increase in ownership of CTMX / CytomX Therapeutics, Inc.

On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 1,930,920 shares of CytomX Therapeutics, Inc. (US:CTMX) valued at $9,075,324 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 1,289,656 shares of CytomX Therapeutics, Inc.. This represents a change in shares of 49.72% during the quarter. The current value of the position is $6,217,562 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F CYTOMX THERAPEUTICS COM 23284F105 1,930,920 641,264 49.72 9,071 65.17 0.0004
2026-02-12 2025-12-31 13F CYTOMX THERAPEUTICS COM 23284F105 1,289,656 838,528 185.87 5,492 281.92 0.0012
2025-11-12 2025-09-30 13F CYTOMX THERAPEUTICS COM 23284F105 451,128 267,962 146.29 1,439 246.51 0.0003
2025-08-12 2025-06-30 13F CYTOMX THERAPEUTICS COM 23284F105 183,166 183,166 416 0.0001
2023-11-09 2023-09-30 13F CYTOMX THERAPEUTICS COM 23284F105 0 -35,865 -100.00 0 -100.00
2023-08-09 2023-06-30 13F CYTOMX THERAPEUTICS COM 23284F105 35,865 -120,591 -77.08 62 -74.15 0.0000
2023-05-12 2023-03-31 13F CYTOMX THERAPEUTICS COM 23284F105 156,456 -16,116 -9.34 236 0.0001
2023-02-09 2022-12-31 13F CYTOMX THERAPEUTICS COM 23284F105 172,572 -8,008 -4.43 0 -100.00 0.0001
2022-11-10 2022-09-30 13F CYTOMX THERAPEUTICS COM 23284F105 180,580 -216,661 -54.54 262 -63.96 0.0001
2022-08-12 2022-06-30 13F CYTOMX THERAPEUTICS COM 23284F105 397,241 -411,899 -50.91 727 -66.36 0.0003
2022-05-13 2022-03-31 13F CYTOMX THERAPEUTICS COM 23284F105 809,140 287,113 55.00 2,161 -4.38 0.0007
2022-02-09 2021-12-31 13F CYTOMX THERAPEUTICS COM 23284F105 522,027 198,998 61.60 2,260 37.47 0.0007
2021-11-12 2021-09-30 13F CYTOMX THERAPEUTICS COM 23284F105 323,029 -311,364 -49.08 1,644 -59.06 0.0005
2021-08-12 2021-06-30 13F CYTOMX THERAPEUTICS COM 23284F105 634,393 119,342 23.17 4,016 0.88 0.0013
2021-05-14 2021-03-31 13F CYTOMX THERAPEUTICS COM 23284F105 515,051 -38,853 -7.01 3,981 9.70 0.0013
2021-03-08 2020-12-31 13F/A-2 CYTOMX THERAPEUTICS COM 23284F105 553,904 -16,700 -2.93 3,629 -4.37 0.0013
2021-02-11 2020-12-31 13F CYTOMX THERAPEUTICS COM 23284F105 553,904 -16,700 3,629 1,310.6019
2020-11-12 2020-09-30 13F CYTOMX THERAPEUTICS COM 23284F105 570,604 0 0.00 3,795 -20.16 0.0016
2020-08-13 2020-06-30 13F CYTOMX THERAPEUTICS COM 23284F105 570,604 -23,063 -3.88 4,753 4.42 0.0021
2020-05-14 2020-03-31 13F CYTOMX THERAPEUTICS COM 23284F105 593,667 24,103 4.23 4,552 -3.82 0.0024
2020-02-14 2019-12-31 13F CYTOMX THERAPEUTICS COM 23284F105 569,564 162,919 40.06 4,733 57.66 0.0017
2019-11-12 2019-09-30 13F CYTOMX THERAPEUTICS COM 23284F105 406,645 57,451 16.45 3,002 -23.36 0.0012
2019-08-13 2019-06-30 13F CYTOMX THERAPEUTICS COM 23284F105 349,194 208,619 148.40 3,917 159.23 0.0015
2019-08-12 2019-03-31 13F/A-2 CYTOMX THERAPEUTICS COM 23284F105 140,575 95,460 211.59 1,511 121.88 0.0006
2019-05-10 2019-03-31 13F CYTOMX THERAPEUTICS COM 23284F105 140,575 95,460 1,511
2019-02-26 2018-12-31 13F/A-1 CYTOMX THERAPEUTICS COM 23284F105 45,115 45,115 681 0.0003
2019-02-13 2018-12-31 13F CYTOMX THERAPEUTICS COM 23284F105 45,115 681 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.